African Journal of Advanced Pure and Applied Sciences (AJAPAS)
Online ISSN: 2957-644X
Volume 2, Issue 3, July-September 2023, Page No: 151-159
Website: *https://aaasjournals.com/index.php/ajapas/index*
||Arab Impact factor 2022: 0.87|| SJIFactor 2023: 5.689|| ISI 2022-2023: 0.557

[Review Articles]

Immunological Insights into Rheumatoid Arthritis: A Comprehensive Review of Diagnosis and Assessment Approaches

Abdullah Salim Al-Karawi [1 *], Yamama Farouk Alawssi [2], Maha Khalid Khadhum [2]
[1] Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq
[2] Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq

[*]*Corresponding author: Abdullah.S.Shaker@uomustansiriyah.edu.iq*

Received: June 09, 2023	Accepted: July 27, 2023	Published: July 29, 2023

Abstract:
This comprehensive review addresses the challenges and future prospects of immunological approaches in the management of Rheumatoid Arthritis (RA). It begins with an introduction to RA as a chronic autoimmune disease characterized by joint inflammation. The complexities of RA diagnosis are emphasized, followed by an exploration of the challenges surrounding treatment response heterogeneity, drug safety, primary non-response and secondary loss of response, optimal timing of therapy initiation, and cost accessibility. The review highlights ongoing efforts to identify biomarkers for personalized therapy, understand underlying mechanisms to enhance treatment efficacy, and optimize patient outcomes. Future perspectives include advancements in precision medicine tailored to individual patients and the development of novel therapeutics targeting specific immune pathways or cell subsets. Continued research collaboration is pivotal for optimizing RA care.

Keywords: Rheumatoid Arthritis, Diagnosis, Anti-CCP, Rheumatoid Factor

Cite this article as: A. S. Al-Karawi, Y. F. Alawssi, M. K. Khadhum, "Immunological Insights into Rheumatoid Arthritis: A Comprehensive Review of Diagnosis and Assessment Approaches", *African Journal of Advanced Pure and Applied Sciences (AJAPAS)*, vol. 2, no. 3, pp. 151 –159, July-September 2023.

الرؤى المناعية في التهاب المفاصل الروماتويدي: استكشاف شامل لنهج التشخيص والتقييم

عبدالله سالم الكروي [1*]، يمامة فاروق الاوسي [2]، مها خالد كاظم [2]
[1] قسم علوم الحياة، كلية العلوم، الجامعة المستنصرية، بغداد، العراق
[2] جامعة ابن سينا للعلوم الطبية والصيدلانية، بغداد، العراق

الملخص
تتناول هذه المراجعة الشاملة التحديات والآفاق المستقبلية للمقاربات المناعية في إدارة التهاب المفاصل الروماتويدي (RA). يبدأ بمقدمة عن التهاب المفاصل الروماتويدي باعتباره أحد أمراض المناعة الذاتية المزمنة التي تتميز بالتهاب المفاصل. تم التأكيد على تعقيدات تشخيص التهاب المفاصل الروماتويدي ، متبوعًا باستكشاف التحديات المحيطة بعدم تجانس استجابة

العلاج ، وسلامة الأدوية ، وعدم الاستجابة الأولية والفقدان الثانوي للاستجابة ، والتوقيت الأمثل لبدء العلاج ، وإمكانية الوصول إلى التكلفة. يسلط الاستعراض الضوء على الجهود الجارية لتحديد المؤشرات الحيوية للعلاج الشخصي ، وفهم الآليات الأساسية لتعزيز فعالية العلاج ، وتحسين نتائج المرضى. تشمل وجهات النظر المستقبلية التطورات في الطب الدقيق المصمم خصيصًا للمرضى وتطوير علاجات جديدة تستهدف مسارات مناعية معينة أو مجموعات فرعية من الخلايا. يعد التعاون البحثي المستمر أمرًا محوريًا لتحسين رعاية التهاب المفاصل الروماتويدي.

الكلمات المفتاحية: التهاب المفاصل الروماتويدي، التشخيص، مضاد CCP، عامل الروماتويد.

1. Introduction

A chronic autoimmune illness known as rheumatoid arthritis (RA) typically affects the tiny joints in the hands and feet and is characterized by inflammation and joint destruction (1). Pain, stiffness in the morning, edema, and decreased joint function are typically the results. Inflammation brought on by the immune system wrongly attacking body tissues, especially the synovium (the lining of the joints), causes RA (2). Approximately 1% of the world's population suffers from RA, and women are more likely than males to be affected (3). The disorder can bring numerous symptoms, such as joint discomfort, edema, stiffness (particularly in the morning or after periods of inactivity), weariness, and general malaise. The symptoms usually occur symmetrically on both sides of the body [2]. Over time, untreated or poorly managed RA can lead to joint deformities and destruction due to persistent inflammation. Diagnosis of RA involves a combination of clinical evaluation, blood tests (such as rheumatoid factor and anti-cyclic citrullinated peptide antibodies), imaging studies (such as X-rays or ultrasound), and assessment of symptoms [4].

While there is no cure for RA yet, various treatment options are available. These include medications such as nonsteroidal anti-inflammatory drugs [NSAIDs], disease-modifying antirheumatic drugs [DMARDs], biological therapies; physical therapy exercises; lifestyle modifications; and sometimes surgery [5]. Managing RA typically involves a multidisciplinary team approach involving rheumatologists, physical therapists, occupational therapists, and sometimes psychologists or social workers to provide comprehensive care [4]. It is important to note that RA can have extra-articular manifestations beyond joint involvement. These can include rheumatoid nodules (subcutaneous lumps), lung involvement (interstitial lung disease), heart problems (rheumatoid vasculitis), eye inflammation (scleritis or uveitis), and systemic effects like fatigue, weight loss, and anemia [1]. Individuals with RA have a higher risk of developing comorbid conditions such as cardiovascular diseases, osteoporosis, infections, depression, and anxiety. It is therefore important to consider holistic management approaches that include lifestyle modifications such as regular exercise tailored to individual abilities, maintaining a healthy diet rich in anti-inflammatory foods, adequate rest, and stress management techniques [6].

The primary objective of the ongoing research is to enhance comprehension of the fundamental mechanisms implicated in rheumatoid arthritis while also striving to augment knowledge regarding advanced diagnostic methodologies and identifying the most efficacious treatment modalities. Additionally, this study aims to address difficulties in the immunological management of rheumatoid arthritis and investigate potential future directions in this field.

2. Immunopathogenesis of Rheumatoid Arthritis

The immune system, genetics, and environmental factors interact intricately in the immunopathogenesis of rheumatoid arthritis (RA). Even though I don't have immediate access to outside sources. Chronic joint inflammation brought on by an autoimmune reaction is a hallmark of RA. The development of RA is thought to be influenced by both hereditary and environmental factors [7, 8]. The risk of having RA has been linked to specific human leukocyte antigen (HLA) genes, including HLA-DRB1 [9].

The immune system’s response in RA involves multiple components, including autoantibodies and pro-inflammatory cytokines. Autoantibodies like rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPAs) are commonly found in individuals with RA, these antibodies target self-proteins that have undergone post-translational modifications called citrullination, the presence of ACPAs is highly specific to RA and can help in clinical diagnosis and predicting disease severity [8]. Inflammation in RA mainly occurs within the synovium, which lines the joint cavities. Activated immune cells infiltrate the synovial membrane, leading to hyperplasia and increased vascularity. Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α),

interleukin-6 (IL-6), and interleukin-17 (IL-17), play a crucial role in promoting inflammation and joint destruction [9], suggesting that genetic predisposition may play a part. Autoantibodies and pro-inflammatory cytokines are just two of the many elements that make up the immune system's response to RA.

The interaction of immune cells, especially T and B cells, also plays a role in the immunopathogenesis of RA. Antigen-presenting cells (APCs) transmit self-antigens, which T cells recognize and activate other immune cells to drive the immune response [10]. However, B cells also contribute to the presentation of antigens to T cells and the production of autoantibodies. The persistent inflammation in RA attracts and activates extra immune cells, such as neutrophils and macrophages. These immune cells release Numerous inflammatory mediators, which feed the inflammatory response and damage tissue [11].

3. Diagnostic Methods for Rheumatoid Arthritis

Rheumatoid Arthritis (RA) diagnostic methods combine clinical evaluation, laboratory tests, and imaging studies.

3.1. Clinical Evaluation: A healthcare expert will perform a complete medical history and physical examination to evaluate symptoms, joint involvement patterns, and disease activity in general. They may assess rheumatoid nodules, other extra-articular symptoms, joint discomfort, swelling, and range-of-motion restrictions. Clinical evaluations may also look at systemic symptoms, weariness, morning stiffness, and the functional impact of RA on daily activities, in addition to joint examinations [12].

3.2. Laboratory Tests:

3.2.1. ***Rheumatoid Factor (RF):*** RF is an autoantibody that attacks the immunoglobulin G (IgG) Fc region. One of the earliest serological indicators to be employed in the diagnosis of RA. This blood test looks for antibodies referred to as rheumatoid factors. About 60-80% of people with RA have RF. However, it can also occur in other diseases [13, 14].

3.2.2. ***Anti-Cyclic Citrullinated Peptide Antibodies (ACPAs):*** A class of autoantibodies known as ACPAs attack citrullinated proteins with particularity. They have developed into useful diagnostic and prognostic biomarkers since they are specific to RA. Testing for ACPAs, such as anti-cyclic citrullinated peptide (anti-CCP) antibodies, has improved the accuracy and early detection of RA. These autoantibodies target citrullinated proteins and are highly specific to RA [15, 16].

3.2.3. ***Acute Phase Reactants***: Blood tests measuring markers of inflammation include C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Elevated levels of these markers are indicative of ongoing inflammation in the body [17].

3.2.4. ***Serological Markers***: Apart from rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPAs), other serological markers may be measured in specific cases. These include antinuclear antibodies (ANA), anti-RA33 antibodies, and anti-citrullinated vimentin antibodies (anti-Sa) [18-20].

3.3. Imaging Studies:

3.3.1. ***X-rays:*** X-ray imaging helps evaluate joint damage such as erosion, joint space narrowing, and bony abnormalities. However, X-rays may not show early signs of RA [21, 22].

3.3.2. ***Ultrasound:*** This imaging method employs sound waves to see inflammatory synovial tissue and find swelling or fluid buildup in joints [21, 22].

3.3.3. ***Magnetic Resonance Imaging (MRI):*** MRI produces fine-grained images that can be used to evaluate soft tissue involvement, joint inflammation, cartilage degradation, and bone erosion. It is especially helpful for diagnosing early-stage illness or monitoring the course of the condition [21, 22].

3.4. Joint Aspiration/Synovial Fluid Analysis: During joint aspiration, a tiny sample of synovial fluid is drawn from a joint that is infected. White blood cell count, crystal analysis (to rule out gout or pseudogout), and infection screening are some of the analyses that help determine whether there are any inflammatory markers present.

3.5. Composite Scoring Systems: To assess disease activity and direct treatment choices, composite scoring systems incorporate multiple clinical and laboratory indicators. Examples are the Clinical Disease Activity Index (CDAI) and the Disease Activity Score based on 28 joints (DAS28) [23].

3.6. Response to Treatment: Monitoring the response to treatment can provide additional insight into confirming the diagnosis of RA. Improvement in symptoms, reduced disease activity scores, or regression in joint damage on imaging can support a diagnosis of RA [24].

3.7. Disease Activity Scores: Scoring systems such as the Disease Activity Score based on 28 joints (DAS28) or Clinical Disease Activity Index (CDAI) are used to evaluate and monitor disease activity over time [25].

3.8. Biopsy: In some cases, a synovial tissue biopsy may be recommended to assess inflammation and rule out other conditions with similar symptoms [26].

3.9. Cytokines: Cytokines are small signaling molecules involved in cell communication during immune responses. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17) have critical roles in promoting inflammation and joint damage in RA. Elevated levels of these cytokines can serve as biomarkers of disease activity and may guide treatment decisions [27]

Table 1. Diagnostic Tests for Rheumatoid Arthritis (RA): Advantages and Disadvantages

Diagnostic Test	Advantages	Disadvantages
Rheumatoid Factor (RF)	• Widely available	• High false-positive rate • Low specificity
Anti-Cyclic Citrullinated Peptide Antibodies (ACPAs)	• Highly specific for RA	• False negatives in early RA
Acute Phase Reactants (C-reactive protein, ESR)	• Indicate presence of inflammation	• Non-specific markers of inflammation • may be elevated in other conditions
Antinuclear Antibodies (ANA)	• Can help identify potential overlap syndromes • or accompanying autoimmune conditions	• Not specific to RA; present in other conditions
Anti-RA33 Antibodies	• May assist in distinguishing subsets of patients with RA	• Limited data and clinical utility
Anti-Citrullinated Vimentin Antibodies (anti-Sa)	• Implicated in joint destruction • Potential prognostic implications	• Limited availability and standardized assays
Imaging Studies	• Detect joint damage	• Costly, may not detect early disease
(X-rays, ultrasound, MRI)	• Assess disease progression	• Radiation exposure with X-rays • Limited sensitivity in early stages
Clinical Evaluation	• Comprehensive assessment by healthcare professional	• Subjective judgments

4. Immunological Approaches for the Treatment of Rheumatoid Arthritis

An Overview Immunological approaches have revolutionized the **treatment** of Rheumatoid Arthritis (RA), targeting specific components of the immune system involved in the pathogenesis of the disease.

4.1. Disease-Modifying Anti-Rheumatic Drugs (DMARDs):

DMARDs are a cornerstone of RA treatment and act by suppressing the underlying autoimmune response. Conventional DMARDs, such as methotrexate, sulfasalazine, and hydroxychloroquine, dampen immune activity and reduce joint inflammation. Targeted synthetic DMARDs (tsDMARDs) such as Janus kinase (JAK) inhibitors inhibit signaling pathways involved in inflammation. Biological DMARDs, including tumor necrosis factor-alpha (TNF-α) inhibitors, interleukin-6 (IL-6) inhibitors, and others, specifically target key immune mediators [28].

4.2. B-cell Depletion Therapy:

B cells play a crucial role in RA pathogenesis through autoantibody production and antigen presentation to T cells. Monoclonal antibodies like rituximab target CD20 on B cells, leading to their depletion and reduction in autoantibody production. B-cell depletion therapy has shown efficacy in controlling disease activity and reducing joint damage in RA [29].

4.3. T-cell Modulation:

T cells orchestrate immune responses in RA by recognizing self-antigens presented by antigen-presenting cells. Abatacept is a fusion protein that blocks co-stimulation signals required for T cell activation [30, 31].

4.4. Cytokine Inhibitors:

Pro-inflammatory cytokines like TNF-α, IL-6, and IL-17 play a crucial role in RA pathogenesis. Targeted biologic agents neutralize or inhibit these cytokines to reduce inflammation and joint damage. Examples include TNF inhibitors (adalimumab, etanercept), IL-6 inhibitors (tocilizumab, sarilumab), and IL-17 inhibitors (secukinumab) [32-34].

4.5. Interleukin-1 (IL-1) Inhibitors:

IL-1 is another pro-inflammatory cytokine involved in RA pathogenesis. IL-1 inhibitors, such as anakinra and canakinumab, block the effects of IL-1, reducing inflammation and joint damage [35].

4.6. Immunomodulatory Therapies:

Immunomodulatory therapies aim to restore immune balance and regulate the immune response in RA. These include agents such as tofacitinib, a Janus kinase (JAK) inhibitor that targets intracellular signaling pathways involved in immune activation [36].

4.7. Co-stimulation Blockade:

Co-stimulation blockade targets the interaction between antigen-presenting cells (APCs) and T cells. Belatacept, another co-stimulation blocker like abatacept, inhibits T cell activation by blocking CD80/86 co-stimulatory molecules on APCs [37].

4.8. Autologous Stem Cell Transplantation:

In severe or refractory cases of RA, autologous stem cell transplantation (ASCT) may be considered. ASCT aims to “reboot” the immune system by using high-dose chemotherapy followed by reinfusion of collected stem cells [38]. This approach has shown promising results in select cases but carries significant risks and is not widely used.

4.9. Personalized Medicine Approaches:

Advances in understanding the genetic and molecular characteristics of RA are leading to personalized medicine approaches. Biomarkers that predict treatment response or disease progression enable tailored therapies for individual patients.

Table 2. Immunological Approaches for the Treatment of Rheumatoid Arthritis: Summary of Therapies

Immunological Approach	Description/Target
Disease-Modifying Anti-Rheumatic Drugs (DMARDs)	Suppress underlying autoimmune response; Conventional DMARDs, Targeted synthetic DMARDs, Biological DMARDs
B-cell Depletion Therapy	Deplete B cells and reduce autoantibody production
T-cell Modulation	Regulate T cell activity and dampen inflammatory response
Cytokine Inhibitors	Neutralize or inhibit pro-inflammatory cytokines
Interleukin-1 (IL-1) Inhibitors	Block the effects of IL-1, reducing inflammation and joint damage
Immunomodulatory Therapies	Restore immune balance and regulate immune response
Co-stimulation Blockade	Block interaction between antigen-presenting cells and T cells
Autologous Stem Cell Transplantation	"Reboot" immune system using high-dose chemotherapy and stem cell reinfusion
Personalized Medicine Approaches	Tailor therapies based on individual patient characteristics

5. Challenges and Future Perspectives in Immunological Approaches for Rheumatoid Arthritis (RA):

Immunological approaches have transformed the management of Rheumatoid Arthritis (RA), improving outcomes for many patients. However, several challenges remain, and ongoing research is focused on addressing these challenges to further enhance treatment strategies.

5.1. Treatment Response Heterogeneity:

- Not all patients respond equally to immunological therapies.
- Identifying biomarkers that can predict treatment response and stratify patients for individualized therapy remains an active area of research [39].
- Genetic, molecular, and clinical factors are being investigated to guide treatment decisions and optimize outcomes.

5.2. Drug Safety and Side Effects:

- Some immunological therapies used in RA management carry potential risks and side effects.
- Long-term safety data are crucial to understand potential risks such as infections, malignancies, or adverse events [40].
- Ongoing pharmacovigilance efforts continue to monitor the safety profiles of these treatments.

5.3. Primary Non-Response and Secondary Loss of Response:

- Some patients may not respond adequately or experience a loss of response over time.
- Understanding the mechanisms underlying primary non-response or secondary loss of response is essential for developing targeted interventions.
- Biomarkers that can predict non-response or loss of response may guide treatment adjustments or the exploration of alternative therapeutic options [41].

5.4. Optimal Timing of Therapy Initiation:

- Identifying the optimal timing for initiating immunological therapies remains a challenge in RA management.
- Early intervention has shown better outcomes in preventing joint damage and achieving disease remission.
- Research efforts focus on identifying early markers that can predict disease progression and inform timely treatment initiation [42].

5.5. Cost Accessibility:

- The cost burden associated with some immunological therapies can limit access for certain patients.
- Continued efforts are needed to improve affordability, broaden insurance coverage, and explore cost-effective treatment strategies.

Future perspectives in the field of immunological approaches for RA include:

- Advancements in precision medicine, tailoring treatments based on individual patient characteristics and disease subtypes.
- Development of novel therapeutics targeting specific immune pathways or cell subsets involved in RA pathogenesis.
- Combination therapies with multiple targets to achieve more comprehensive disease control and better long-term outcomes.

These challenges and future perspectives highlight the need for ongoing research, collaboration across disciplines, and continuous evaluation of therapeutic strategies to optimize the care of individuals with RA.

Author Contributions

Every author involved in this study made significant contributions to the planning and execution of the research, data collection, as well as data analysis and interpretation. They all had a hand in either writing the initial manuscript or critically reviewing it for key intellectual content. They approved its submission to the present journal and committed to being responsible for every aspect of the work.

Acknowledgments

We thank Mustansiriyah University in Baghdad/Iraq (http://uomustansiriyah.edu.iq) for its support to achievement this work.

References

[1] A. Conforti *et al.*, "Beyond the joints, the extra-articular manifestations in rheumatoid arthritis," *Autoimmunity reviews*, vol. 20, no. 2, p. 102735, 2021.
[2] M. Gulati, Z. Farah, and M. Mouyis, "Clinical features of rheumatoid arthritis," *Medicine*, vol. 46, no. 4, pp. 211-215, 2018.
[3] E. L. Rowbotham and A. J. Grainger, "Rheumatoid arthritis: ultrasound versus MRI," *American Journal of Roentgenology*, vol. 197, no. 3, pp. 541-546, 2011.
[4] V. Majithia and S. A. Geraci, "Rheumatoid arthritis: diagnosis and management," *The American journal of medicine*, vol. 120, no. 11, pp. 936-939, 2007.
[5] E. Zampeli, P. G. Vlachoyiannopoulos, and A. G. Tzioufas, "Treatment of rheumatoid arthritis: unraveling the conundrum," *Journal of autoimmunity*, vol. 65, pp. 1-18, 2015.
[6] J. H. Klippel, J. H. Stone, L. J. Crofford, and P. H. White, "Primer on the rheumatic diseases," 2008.
[7] I. B. McInnes and G. Schett, "The pathogenesis of rheumatoid arthritis," *New England Journal of Medicine*, vol. 365, no. 23, pp. 2205-2219, 2011.
[8] E. Choy, "Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis," *Rheumatology*, vol. 51, no. suppl_5, pp. v3-v11, 2012.
[9] Y. Okada, S. Eyre, A. Suzuki, Y. Kochi, and K. Yamamoto, "Genetics of rheumatoid arthritis: 2018 status," *Annals of the rheumatic diseases*, vol. 78, no. 4, pp. 446-453, 2019.
[10] A.-L. Mueller *et al.*, "Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies," *Cells*, vol. 10, no. 11, p. 3017, 2021.
[11] E. H. Noss and M. B. Brenner, "The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis," *Immunological reviews*, vol. 223, no. 1, pp. 252-270, 2008.
[12] A.-F. Radu and S. G. Bungau, "Management of rheumatoid arthritis: an overview," *Cells*, vol. 10, no. 11, p. 2857, 2021.
[13] N. Oskam *et al.*, "Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity," *Annals of the Rheumatic Diseases*, vol. 82, no. 7, pp. 945-956, 2023.
[14] G. Espinoza, G. Maldonado, J. Narvaez, R. Guerrero, G. Citera, and C. Rios, "Beyond rheumatoid arthritis evaluation: what are we missing?," *Open access rheumatology: research and reviews*, pp. 45-55, 2021.
[15] K. Nishimura *et al.*, "Meta-analysis: diagnostic accuracy of anti–cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis," *Annals of internal medicine*, vol. 146, no. 11, pp. 797-808, 2007.

[16] L. M. Jansen, D. Van Schaardenburg, I. van der Horst-Bruinsma, R. J. van der Stadt, M. H. De Koning, and B. A. Dijkmans, "The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis," *The Journal of rheumatology,* vol. 30, no. 8, pp. 1691-1695, 2003.
[17] S. Yardim-Akaydin, E. Caliskan-Can, H. Firat, S. Ardiç, and B. Simsek, "Influence of gender on C-reactive protein, fibrinogen, and erythrocyte sedimentation rate in obstructive sleep apnea," *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Inflammatory and Anti-Allergy Agents),* vol. 13, no. 1, pp. 56-63, 2014.
[18] C. T. Aitcheson, C. Peebles, F. Joslin, and E. M. Tan, "Characteristics of antinuclear antibodies in rheumatoid. arthritis," *Arthritis & Rheumatism,* vol. 23, no. 5, pp. 528-538, 1980.
[19] W. Hassfeld *et al.*, "Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis," *Arthritis & Rheumatism: Official Journal of the American College of Rheumatology,* vol. 32, no. 12, pp. 1515-1520, 1989.
[20] H. S. El-Gabalawy and J. A. Wilkins, "Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis," *Arthritis Res Ther,* vol. 6, no. 2, pp. 1-4, 2004.
[21] B. Taouli *et al.*, "Rheumatoid arthritis of the hand and wrist: comparison of three imaging techniques," *American Journal of Roentgenology,* vol. 182, no. 4, pp. 937-943, 2004.
[22] B. Weissman, "Imaging techniques in rheumatoid arthritis," *The Journal of rheumatology. Supplement,* vol. 42, pp. 14-19, 1994.
[23] P. Mandl *et al.*, "Clinical and Ultrasound-Based Composite Disease Activity Indices in Rheumatoid Arthritis: Results From a Multicenter, Randomized Study," *Arthritis Care & Research,* vol. 65, no. 6, pp. 879-887, 2013, doi: https://doi.org/10.1002/acr.21913.
[24] Y. J. Lin, M. Anzaghe, and S. Schülke, "Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis," (in eng), *Cells,* vol. 9, no. 4, Apr 3 2020, doi: 10.3390/cells9040880.
[25] J. Anderson *et al.*, "Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice," *Arthritis care & research,* vol. 64, no. 5, pp. 640-647, 2012.
[26] S. Bugatti *et al.*, "Synovial tissue heterogeneity and peripheral blood biomarkers," *Current rheumatology reports,* vol. 13, pp. 440-448, 2011.
[27] N. Kondo, T. Kuroda, and D. Kobayashi, "Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis," (in eng), *Int J Mol Sci,* vol. 22, no. 20, Oct 10 2021, doi: 10.3390/ijms222010922.
[28] O. Benjamin, A. Goyal, and S. L. Lappin, "Disease modifying anti-rheumatic drugs (DMARD)," 2018.
[29] B. L. Kotzin, "The role of B cells in the pathogenesis of rheumatoid arthritis," *The Journal of Rheumatology Supplement,* vol. 73, pp. 14-18, 2005.
[30] M. Fabbri, C. Smart, and R. Pardi, "T lymphocytes," *The international journal of biochemistry & cell biology,* vol. 35, no. 7, pp. 1004-1008, 2003.
[31] D. Su, M. Shen, X. Li, and L. Sun, "Roles of T cells in the pathogenesis of autoimmune diseases," *Journal of Immunology Research,* vol. 2013, 2013.
[32] Y.-F. Chen *et al.*, "A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness," *Health technology assessment (Winchester, England),* vol. 10, no. 42, pp. iii-iv, xi, 2006.
[33] Y. Tanaka and E. M. Mola, "IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab," vol. 73, ed: BMJ Publishing Group Ltd, 2014, pp. 1595-1597.
[34] B. Schminke, S. Trautmann, B. Mai, N. Miosge, and S. Blaschke, "Interleukin 17 inhibits progenitor cells in rheumatoid arthritis cartilage," *European journal of immunology,* vol. 46, no. 2, pp. 440-445, 2016.
[35] N. Nishimoto, "Interleukin-6 as a therapeutic target in candidate inflammatory diseases," *Clinical Pharmacology & Therapeutics,* vol. 87, no. 4, pp. 483-487, 2010.
[36] G. R. Burmester *et al.*, "Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial," *The Lancet,* vol. 381, no. 9865, pp. 451-460, 2013.
[37] F. Vincenti *et al.*, "Belatacept and long-term outcomes in kidney transplantation," *New England Journal of Medicine,* vol. 374, no. 4, pp. 333-343, 2016.
[38] J. Snowden *et al.*, "Autologous stem cell transplantation in severe treatment-resistant Crohn's disease: long-term follow-up of UK patients treated on compassionate basis," *QJM: An International Journal of Medicine,* vol. 107, no. 11, pp. 871-877, 2014.
[39] J. D. Isaacs, "The changing face of rheumatoid arthritis: sustained remission for all?," *Nature Reviews Immunology,* vol. 10, no. 8, pp. 605-611, 2010.
[40] J. Bullock *et al.*, "Rheumatoid Arthritis: A Brief Overview of the Treatment," (in eng), *Med Princ Pract,* vol. 27, no. 6, pp. 501-507, 2018, doi: 10.1159/000493390.

[41] S. Raychaudhuri, "Recent advances in the genetics of rheumatoid arthritis," (in eng), *Curr Opin Rheumatol*, vol. 22, no. 2, pp. 109-18, Mar 2010, doi: 10.1097/BOR.0b013e328336474d.

[42] J. L. Nam *et al.*, "Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA," (in eng), *Ann Rheum Dis*, vol. 69, no. 6, pp. 976-86, Jun 2010, doi: 10.1136/ard.2009.126573.